Oxcarbazepine
Product Images NDC 50268-649

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Oxcarbazepine (NDC 50268-649). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avpak, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

30 (649 30)

Label of Oxcarbazepine Oral Suspension, USP 300 mg/5 mL by AvPAK. The label states the suspension delivers 5 mL per dose and contains 300 mg of oxcarbazepine per 5 mL. It includes storage instructions and a note to shake well before use. The package size is 30 units of 5 mL.*

FDA Label Image

9f14a9c2-figure-01 (Oxcarbazepine Oral Suspension Usp 1)

Chemical structure of oxcarbazepine consisting of two benzene rings connected through a seven-membered ring with a ketone group and a carbamoyl group attached to the nitrogen atom.*

FDA Label Image

9f14a9c2-figure-02 (Oxcarbazepine Oral Suspension Usp 2)

A Kaplan-Meier plot showing exit rates over time from Day 2 to Day 11 at 8 am for two treatment groups: Oxcarbazepine (solid line) and Placebo (dashed line). The graph includes a log-rank test p-value of 0.0001, indicating statistical comparison between groups.*

FDA Label Image

9f14a9c2-figure-03 (Oxcarbazepine Oral Suspension Usp 3)

A line graph depicting seizure rate over days from the first dose to the first seizure in treatment groups receiving Oxcarbazepine and Placebo. The x-axis represents days, while the y-axis shows seizure rate. The graph compares seizure rates between the two groups, including a log-rank test p-value of 0.046.*

FDA Label Image

9f14a9c2-figure-04 (Oxcarbazepine Oral Suspension Usp 4)

A Kaplan-Meier plot showing exit rate over time in days, comparing two treatment groups labeled HIGH (solid line) and LOW (dotted line). The chart includes a log-rank test p-value of 0.0001 indicating statistical comparison between the groups.*

FDA Label Image

9f14a9c2-figure-05 (Oxcarbazepine Oral Suspension Usp 5)

A Kaplan-Meier curve chart depicting exit rates over time in days for two treatment groups labeled HIGH and LOW. The x-axis represents time to exit in days, and the y-axis shows the exit rate. The LOW group shows a quicker increase in exit rate compared to the HIGH group, with a log-rank test p-value of 0.0001 displayed on the chart.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.